FDA approved first therapy for children with debilitating and disfiguring rare disease
On Apr. 13, 2020, the U.S. Food and Drug Administration (FDA) announced that given the increased demand for…
RedHill Biopharma reported the first two patients treated with opaganib at a leading hospital in Israel
On Apr. 13, 2020, RedHill Biopharma announced the first two patients were treated with opaganib at a leading…
Blackstone and Alnylam announced $2 billion strategic financing collaboration to accelerate advancement of RNAi therapeutics
On Apr. 13, 2020, Blackstone and Alnylam Pharma announced a broad strategic collaboration under which Blackstone will provide…
Mayo Clinic Laboratories launched serology testing in support of COVID-19 response
On Apr. 13, 2020, a new serology test from Mayo Clinic Laboratories that is used to identify the…
Data on 53 patients treated with investigational antiviral remdesivir through Compassionate Use Program published in NEJM
On Apr. 10, 2020, Gilead Sciences announced results from a cohort analysis of 53 patients hospitalized with severe…
IHME released updated COVID-19 predictions for deaths and hospital use in the European Economic Area
On Apr. 10, 2020, the Institute for Health Metrics and Evaluation (IHME) released updated COVID-19 predictions for deaths…
NIH began clinical trial of hydroxychloroquine as potential therapy for COVID-19
On Apr. 9, 2020, the first participants were enrolled in the trial at Vanderbilt University Medical Center, Nashville,…
Fujifilm announced the start of a phase II clinical trial of its influenza antiviral drug ‘Avigan’ Tablet for COVID-19 patients in the U.S.
On Apr. 9, 2020, FUJIFILM announced initiation of a U.S. phase II clinical trial to evaluate the safety…
Laurent Pharmaceuticals joined battle against COVID-19
On Apr. 9, 2020, Laurent Pharmaceuticals announced that a spin off from McGill University planned to test its…
Codex DNA announced new products to support the scientific community’s battle against COVID-19
On Apr. 9, 2020, Codex DNA announced a newly developed and released suite of products and services designed…
Positive data generated by Biosig subsidiary ViralClear on Covid-19 Coronavirus published in bioRxiv
On Apr. 9, 2020, BioSig Technologies announced that an article titled “The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications”…
Washington University launched Clinical trial to evaluate COVID-19 treatment
On Apr. 9, 2020, Washington University School of Medicine in St. Louis launched a clinical trial for patients…
LabCorp and Ciox Health announced an agreement to create a comprehensive COVID-19 patient data registry
On Apr. 9, 2020, LabCorp and Ciox Health announced an agreement to collaborate on a comprehensive U.S.-based COVID-19…
BioCryst began clinical trial with Galidesivir for treatment of patients with COVID-19
On Apr. 9, 2020, BioCryst Pharmaceuticals announced the company has opened enrollment into a randomized, double-blind, placebo-controlled clinical…
Pfizer and BioNTech announced details on collaboration to accelerate global COVID-19 vaccine development
On Apr. 9, 2020, Pfizer and BioNTech disclosed additional details of their collaboration to advance candidates from BioNTech’s…
iBio announced signing of agreements with Infectious Disease Research Institute in support of iBio’s SARS-CoV-2 Virus-Like Particle vaccine development
On Apr. 9, 2020, iBio announced the signing of two agreements with the Infectious Disease Research Institute (IDRI)…
Severely Ill COVID-19 patient at Southern California medical center extubated three days after treatment with CytoDyn’s leronlimab
On Apr. 9, 2020, CytoDyn announced a patient with severe COVID-19 under the care of a leading medical…
Blood samples for Severely Ill COVID-19 patients indicate leronlimab has significantly reduced the Cytokine Storm in all patients
On Apr. 9, 2020, CytoDyn announced results of immunological metrics from blood samples of seven severely ill COVID-19…
Chugai started phase III clinical trial of Actemra for COVID-19 pneumonia in Japan
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
Mateon expanded its COVID-19 therapeutic program to include Artemisinin
On Apr. 8, 2020, Mateon Therapeutics announced that its COVID-19 directed antiviral screening program discovered that Artemisinin is…
Texas A&M Researchers designed 3D-printed diffuser to treat COVID-19 patients
On Apr. 8, 2020, a team of Texas A&M University researchers led by Michael R. Moreno, in collaboration…
Biotechnology | COVID-19 | FDA | Therapeutics
Karyopharm to evaluate low dose Selinexor as potential treatment for hospitalized patients with COVID-19
On Apr. 7, 2020, Karyopharm Therapeutics announced plans to initiate a global randomized clinical trial for low dose…
COVID-19 | FDA | Therapeutics
Cumberland Pharma expanded availability of Vaprisol to treat Hyponatremia for critical care COVID-19 patients
On Apr. 7, 2020, Cumberland Pharma announced an initiative to increase availability of Vaprisol (conivaptan hydrochloride) injection for…
FDA approved Emory University human clinical trials for Emory COVID-19 antiviral
On Apr. 7, 2020, the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug application by…
Seattle area philanthropists responded to COVID-19 care and research needs
On Apr. 7, 2020, the University of Washington Medicine (UW) announced that more than $20 million has been…
Alzheimer’s trial screening data links high amyloid levels with early stage disease
On Apr. 6, 2020, the first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study…
Redhill Biopharma announced first Covid-19 patient treated with Opaganib in Israel under Compassionate Use
On Apr. 6, 2020, RedHill Biopharma announced the first patient with confirmed coronavirus (COVID-19) diagnosis had been dosed…
RedHill Biopharma announced approval of Compassionate Use of Opaganib for COVID-19 in Italy
On Apr. 6, 2020, RedHill Biopharma announced it has received authorization from the Italian National Institute for Infectious…
COVID-19 | FDA | Therapeutics
FDA cleared Mesoblast IND for remestemcel use in COVID-19 ARDS patients
On Apr. 6, 2020, Mesoblast announced it had received clearance from the U.S. Food and Drug Administration (FDA)…
Mateon achieved milestone in development of OT-101, a phase 3 clinical drug candidate, against COVID-19
On Apr. 6, 2020, Mateon Therapeutics announced an update on its rapid antiviral response program targeting coronaviruses, initially…